BioVie to Host Conference Call to Discuss Topline Data from Phase 2 ADDRESS-LC Trial and the Potential of Bezisterim in Long Covid
Go back to BioVie to Host Conference Call to Discuss Topline Data from Phase 2 ADDRESS-LC Trial and the Potential of Bezisterim in Long Covid| (NASDAQ: BIVI) | Delayed: 1.61 -0.17 (9.55%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.78 | 52 Week High | $0.40 | |||
| Open | $1.78 | 52 Week Low | $0.17 | |||
| Day High | $1.84 | P/E | N/A | |||
| Day Low | $1.61 | EPS | $0.00 | |||
| Volume | 406,240 | |||||
